ArticleClinical cancer research : an official journal of the American Association for Cancer Research2014
In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Whole-body tomographic fluorescence lifetime imaging of PD-L1 expression.Research square · 2026Article
- High-speed wide-field fluorescence lifetime imaging for intraoperative tumor visualization and in vivo multiplexing.Biomedical optics express · 2025Article
- First Clinical Results of Fluorescence Lifetime-enhanced Tumor Imaging Using Receptor-targeted Fluorescent Probes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Magnetic Nanoparticles Used in Oncology.Materials (Basel, Switzerland) · 2021Review
- Fluorescence lifetime imaging with a megapixel SPAD camera and neural network lifetime estimation.Scientific reports · 2020Article
- Enrichment of rare events using a multi-parameter high throughput microfluidic droplet sorter.Lab on a chip · 2020Article
- Fluorescence Lifetime-Based Tumor Contrast Enhancement Using an EGFR Antibody-Labeled Near-Infrared Fluorophore.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- A thermo-sensitive fluorescent agent based method for excitation light leakage rejection for fluorescence molecular tomography.Physics in medicine and biology · 2019Article
- A Point-of-Care Device for Molecular Diagnosis Based on CMOS SPAD Detectors with Integrated Microfluidics.Sensors (Basel, Switzerland) · 2019Article
- Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors.EJNMMI research · 2018Article
- Receptor Occupancy Imaging Studies in Oncology Drug Development.The AAPS journal · 2018Review
- Analysis of Flow Cytometric Fluorescence Lifetime with Time-Delay Estimation of Pulse Signals.Sensors (Basel, Switzerland) · 2018Article
- Development of Low-Cost Instrumentation for Single Point Autofluorescence Lifetime Measurements.Journal of fluorescence · 2017Article
- Representation Method for Spectrally Overlapping Signals in Flow Cytometry Based on Fluorescence Pulse Time-Delay Estimation.Sensors (Basel, Switzerland) · 2016Article
- Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances.Materials today (Kidlington, England) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeAdvances in tumor biology created a foundation for targeted therapy aimed at inactivation of specific molecular mechanisms responsible for cell malignancy. In this paper, we used in vivo fluorescence lifetime imaging with HER2-targeted fluorescent probes as an alternative imaging method to investigate the efficacy of targeted therapy with 17-DMAG (an HSP90 inhibitor) on tumors with high expression of HER2 receptors. EXPERIMENTAL
designHER2-specific Affibody, conjugated to Alexafluor 750, was injected into nude mice bearing HER2-positive tumor xenograft. The fluorescence lifetime was measured before treatment and monitored after the probe injections at 12 hours after the last treatment dose, when the response to the 17-DMAG therapy was the most pronounced as well as a week after the last treatment when the tumors grew back almost to their pretreatment size.
resultsImaging results showed significant difference between the fluorescence lifetimes at the tumor and the contralateral site (∼0.13 ns) in the control group (before treatment) and 7 days after the last treatment when the tumors grew back to their pretreatment dimensions. However, at the time frame that the treatment had its maximum effect (12 hours after the last treatment), the difference between the fluorescence lifetime at the tumor and contralateral site decreased to 0.03 ns.
conclusionsThe results showed a good correlation between fluorescence lifetime and the efficacy of the treatment. These findings show that in vivo fluorescence lifetime imaging can be used as a promising molecular imaging tool for monitoring the treatment outcome in preclinical models and potentially in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.